{"filing":{"accession_number":"0001689548-26-000072","cik":"0001689548","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"prax-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000072/prax-20260707.htm"},"events":[{"id":16504,"run_id":14748,"accession_number":"0001689548-26-000072","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Praxis announced a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, complemented by an equity investment in Remagine. This is a material strategic partnership and product development initiative that expands the company's pipeline and competitive positioning, but does not fit the specific operational categories (workforce reduction, restructuring) or other named event types. The collaboration and equity investment represent a significant operational and strategic commitment to advance the ulixacaltamide franchise.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14624,"accession_number":"0001689548-26-000072","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Praxis announced a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, complemented by an equity investment in Remagine. This is a material strategic partnership and product development initiative that expands the company's pipeline and competitive positioning, but does not fit the specific operational categories (workforce reduction, restructuring) or other named event types. The collaboration and equity investment represent a significant operational and strategic commitment to advance the ulixacaltamide franchise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:05:40.446493+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14624,"accession_number":"0001689548-26-000072","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Praxis announced a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, complemented by an equity investment in Remagine. This is a material strategic partnership and product development initiative that expands the company's pipeline and competitive positioning, but does not fit the specific operational categories (workforce reduction, restructuring) or other named event types. The collaboration and equity investment represent a significant operational and strategic commitment to advance the ulixacaltamide franchise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T21:05:40.446493+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-07-07"}]}